专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明公开

EP3218472A2 TAG REMOVAL FROM PROTEINS EXPRESSED IN PRO- AND EUKARYOTIC HOSTS 有权
标题翻译：从正常和非正常宿主中表达的蛋白质去除TAG
公开(公告)号：EP3218472A2
公开(公告)日：2017-09-20
申请号：EP15801694.9
申请日：2015-11-10
申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
发明人： FREY, Steffen , GOERLICH, Dirk
IPC分类号： C12N9/50 , C12N9/64 , C07K1/22
摘要： The present invention belongs to the field of biotechnology. More specifically, the present invention provides a protease, a non-naturally occurring fusion protein comprising a corresponding protease recognition site, expression vectors encoding same, host cells comprising said expression vectors, kit of parts as well as methods applying the protease, fusion protein, and uses thereof, as defined in the claims. The presently disclosed protease/protease recognition site is particularly useful in methods requiring an orthogonal set of proteases, and is suitable for use in both prokaryotic and selected eukaryotic expression systems.
摘要翻译：本发明属于生物技术领域。更具体地，本发明提供蛋白酶，包含相应蛋白酶识别位点的非天然存在的融合蛋白，编码其的表达载体，包含所述表达载体的宿主细胞，部分试剂盒以及应用蛋白酶，融合蛋白，及其用途，如权利要求中所定义的。目前公开的蛋白酶/蛋白酶识别位点在需要正交蛋白酶组的方法中特别有用，并且适用于原核和选择的真核表达系统。

82. 发明公开

EP3214443A1 RHEUMATOID ARTHRITIS MARKER 审中-公开
标题翻译：类风湿关节炎标志物
公开(公告)号：EP3214443A1
公开(公告)日：2017-09-06
申请号：EP15854205.0
申请日：2015-10-29
申请人： National Institute of Advanced Industrial Science and Technology , Keio University , GlycoBiomarker Leading Innovation Co., Ltd.
发明人： KUNO, Atsushi , MATSUDA, Atsushi , NARIMATSU, Hisashi , TAKEUCHI, Tsutomu , SUZUKI, Katsuya , TAKESHITA, Masaru
IPC分类号： G01N33/564 , C07K14/42 , C12N9/64 , G01N33/53 , G01N33/573
CPC分类号： G01N33/573 , C07K14/42 , C07K16/40 , C12N9/64 , C12Y304/24017 , G01N33/53 , G01N33/564 , G01N2333/96494 , G01N2800/102
摘要： The present invention addresses the problem of providing a method whereby disease activity of rheumatoid arthritis is evaluated reliably and with good sensitivity by a simple method, and a kit for use in the method. The present invention furthermore provides a method for accurate diagnosis of polymyalgia rheumatica and relapsing polychondritis, which are similar rheumatic diseases, a method for differentiating rheumatoid arthritis, and a kit for use in the same. The present invention provides a Jacalin-binding O-linked oligosaccharide epitope as a negative marker for diagnosing rheumatoid arthritis, and enables more accurate assessment of disease condition by more objectively determining disease activity of rheumatoid arthritis using the amount of variation of a value obtained by multiplying the amount of MMP-3 in the blood or the amount of bound MMP-3 and ABA, ACA, or ACG in the blood by the reciprocal of the amount of bound MMP-3 and Jacalin in the blood. Through the discovery that an LEL or STL-reactive sugar chain on MMP-3 in the blood is a sugar chain marker for diagnosing polymyalgia rheumatica and relapsing polychondritis, the present invention also provides a method for accurate diagnosis of polymyalgia rheumatica and relapsing polychondritis. The present invention furthermore provides a method for accurate diagnosis of rheumatoid arthritis capable of differentiating between similar rheumatic diseases, by measuring the ratio of the amount of LEL or STL bound on MMP-3 and the amount of Jacalin, ACG, or the like bound on MMP-3 in the blood.
摘要翻译：本发明解决了提供一种方法的问题，该方法通过简单的方法可靠且以良好的灵敏度评估类风湿性关节炎的疾病活性，以及用于该方法的试剂盒。本发明还提供了用于准确诊断风湿性多肌痛和类风湿性疾病的复发性多软骨炎的方法，用于区分类风湿性关节炎的方法和用于其的试剂盒。本发明提供了一种结合Jacalin的O-连接寡糖表位作为诊断类风湿性关节炎的阴性标记物，并且通过使用通过将类风湿性关节炎相关的数值的变化量更加客观地确定类风湿性关节炎的疾病活性，能够更准确地评估疾病状态血液中MMP-3的量或血液中结合的MMP-3和ABA，ACA或ACG的量由血液中结合的MMP-3和Jacalin的量的倒数决定。通过发现血液中MMP-3上的LEL或STL-反应性糖链是诊断风湿性多动脉炎和复发性多软骨炎的糖链标志物，本发明还提供了用于准确诊断风湿性多肌痛和复发性多软骨炎的方法。本发明进一步提供了一种通过测量与MMP-3结合的LEL或STL的量与结合的Jacalin，ACG等的量之比来准确诊断能够区分类风湿性疾病的类风湿性关节炎的方法 MMP-3在血液中。

83. 发明授权

EP2235197B1 CELL CULTURE PROCESSES 有权转让
标题翻译：细胞培养过程
公开(公告)号：EP2235197B1
公开(公告)日：2017-07-26
申请号：EP08868009.5
申请日：2008-12-22
申请人： Baxalta GmbH , Baxalta Incorporated
发明人： GIOVAGNOLI, Andre , ROY, Sylvain , DUCROS, Veronique , CHARLOT, Virginie , STAUFFER, Yves-Olivier
IPC分类号： C12N9/64 , C12P21/02
CPC分类号： C07K14/755 , C12N9/6437 , C12N9/6454 , C12N9/6489 , C12P21/00 , C12P21/02 , C12Y304/21021 , C12Y304/21075 , C12Y304/24087

84. 发明公开

EP3192802A1 STABILIZED PEPTIDE DERIVATIVES 审中-公开
标题翻译：稳定的多肽衍生物
公开(公告)号：EP3192802A1
公开(公告)日：2017-07-19
申请号：EP17152060.4
申请日：2017-01-18
申请人： Bicycle Therapeutics Limited
发明人： Teufel, Daniel , Baldassarre, Leonardo , Mudd, Gemma , Pavan, Silvia
IPC分类号： C07K7/08 , C12N9/64
CPC分类号： C07K7/08 , A61K47/54 , C12N9/6491
摘要： A compound comprising at least one looped peptide structure attached via at least two sulfone linkages formed through cysteine residues of the peptide to a scaffold, wherein the looped peptide comprises an amino acid sequence of formula (I):

-C i -X-U/O-X-X-G-C ii -E-D-F-Y-X-X-C iii - (SEQ ID NO: 1) (I)

or a modified derivative, or pharmaceutically acceptable salt, thereof;
wherein:
C i , C ii and C iii represent first, second and third cysteine residues, respectively;
X represents any amino acid residue;
U represents a polar, uncharged amino acid residue selected from N, C, Q, M, S and T; and
O represents a non-polar aliphatic amino acid residue selected from G, A, I, L, P and V.
Preferably, the compound is a bicyclic peptide having two peptide loops between three sulfone linkages to the scaffold.
摘要翻译：包含至少一个环状肽结构的化合物，所述环状肽结构经由通过所述肽的半胱氨酸残基形成的至少两个砜键连接至支架，其中所述环状肽包含式（I）的氨基酸序列：-Ci-XU / OXXG-Cii -EDFYXX-Ciii-（SEQ ID NO：1）（I）或其修饰衍生物或其药学上可接受的盐; 其中：C 1，C 11和C 11分别代表第一，第二和第三半胱氨酸残基; X代表任何氨基酸残基; U代表选自N，C，Q，M，S和T的极性不带电荷的氨基酸残基; O代表选自G，A，I，L，P和V的非极性脂肪族氨基酸残基。优选地，该化合物是在与支架的三个砜键之间具有两个肽环的双环肽。

85. 发明公开

EP3106515A4 METHOD FOR PREPARING FERMENTATION BROTH EXTRACTS HAVING CHYMOSIN ACTIVITY AND PRODUCTS THEREOF 有权
标题翻译： VERFAHREN ZUR HERSTELLUNG VONFERMENTIERUNGSBRÜHEEXTRAKTENMIT CHYMOSINWIRKUNG UND PRODUKTEN DARAUS
公开(公告)号：EP3106515A4
公开(公告)日：2017-07-12
申请号：EP14879588
申请日：2014-07-02
申请人： BRIGHT DAIRY & FOOD CO LTD
发明人： HANG FENG , GUO BENHENG , LIU ZHENMIN , CHEN WEI , WANG QINBO , SONG XIN , WU ZHENGJUN , ZHANG HAO , ZHU JUNWEI
IPC分类号： C12N1/20 , A23C19/032 , C12N9/64 , C12R1/01
CPC分类号： A23C19/0326 , C12N9/6483 , C12R1/01 , C12Y304/23004
摘要： Provide in the present invention is a method for preparing fermentation broth extracts having milk-clotting activity, comprising the steps of: obtaining the fermentation broth by culturing Paenibacillus CGMCC No. 8333 using a wheat bran broth, and obtaining the extracts by taking the supernatant after centrifuging the resulting fermentation broth. Using these fermentation broth extracts, liquid milk can curdle in a short time, and non-specific hydrolysis of casein is low.
摘要翻译：本发明提供一种制备具有凝乳活性的发酵液提取物的方法，该方法包括以下步骤：通过使用麦麸肉汤培养类芽孢杆菌CGMCC No.8333获得发酵液，并且通过取上清液后获得提取物离心所得发酵液。使用这些发酵液提取物，液态奶可以在短时间内凝结，酪蛋白的非特异性水解低。

86. 发明授权

EP2288615B1 SELECTIVE CASPASE INHIBITORS AND USES THEREOF 失效转让
标题翻译：选择性CASPASE抑制剂及其用途
公开(公告)号：EP2288615B1
公开(公告)日：2017-06-21
申请号：EP09749369.6
申请日：2009-05-21
申请人： Genesis Technologies Limited
发明人： AHLFORS, Jan-Eric , MEKOUAR, Khalid
IPC分类号： C07K7/06 , A61K31/223 , A61K31/47 , A61K31/5375 , A61K31/662 , A61K38/00 , C07C237/12 , C07C237/20 , C07C317/48 , C07D215/14 , C07D295/26 , C07F9/40 , C07K5/08 , C07K5/10 , C07K14/81 , C12N9/64
CPC分类号： C07K5/0819 , A61K38/00 , A61K38/005 , C07C271/22 , C07C317/50 , C07C2602/08 , C07D209/16 , C07D213/81 , C07D215/12 , C07D295/26 , C07F9/4006 , C07F9/6533 , C07K5/0202 , C07K5/06034 , C07K5/06052 , C07K5/06078 , C07K5/06104 , C07K5/06139 , C07K5/081 , C07K5/0812 , C07K5/1013 , C07K14/8139
摘要： The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).
摘要翻译：本发明涉及式I，IA，II，IIA，III或IIIA的化合物及其药物用途。本发明的具体方面涉及这些化合物用于选择性抑制一种或多种半胱天冬酶的用途。还描述了其中式I，IA，II，IIA，III或IIIA的化合物用于预防和/或治疗受试者中的各种疾病和病症的方法，所述疾病和病症包括半胱天冬酶介导的疾病例如败血症，心肌梗塞，缺血性中风，脊髓损伤（SCI），创伤性脑损伤（TBI）和神经退行性疾病（例如多发性硬化症（MS）和阿尔茨海默病，帕金森病和亨廷顿病）。

87. 发明公开

EP3178835A1 EXTENDED RECOMBINANT POLYPEPTIDES AND COMPOSITIONS COMPRISING SAME 有权转让
标题翻译：扩展重组多肽和包含其的组合物
公开(公告)号：EP3178835A1
公开(公告)日：2017-06-14
申请号：EP16189957.0
申请日：2010-02-03
申请人： Amunix Operating Inc.
发明人： SCHELLENBERGER, Volker , SILVERMAN, Joshua , WANG, Chia-wei , SPINK, Benjamin , STEMMER, Willem , GEETHING, Nathan , TO, Wayne , CLELAND, Jeffrey
IPC分类号： C07K1/00 , C07K14/00 , C07K17/00 , C07K14/47 , C12N15/62 , C07K14/605 , C07K14/745 , C07K14/61 , C07K14/545 , C07K14/50 , C07K14/58 , C12N9/64
CPC分类号： C07K14/47 , C07K14/001 , C07K14/545 , C07K14/605 , C07K14/61 , C07K14/745 , C07K2319/31 , C07K2319/35 , C12N9/6437 , C12N9/644
摘要： The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
摘要翻译：本发明涉及包含与延伸重组多肽（XTEN）连接的生物活性蛋白的组合物，编码所述组合物和载体的分离的核酸以及含有所述组合物的载体和宿主细胞，以及使用所述组合物治疗葡萄糖相关疾病，代谢疾病，凝血障碍和生长激素相关的障碍和病症。

88. 发明授权

EP2245052B1 SELECTIVE EXOSITE INHIBITION OF PAPP-A ACTIVITY AGAINST IGFBP-4 有权
标题翻译：选择性抑制PAPP-A活性对IGFBP-4的抑制作用
公开(公告)号：EP2245052B1
公开(公告)日：2017-05-24
申请号：EP09703361.7
申请日：2009-01-23
申请人： Aarhus Universitet
发明人： OXVIG, Claus , MIKKELSEN, Jakob Hauge , NIELSEN, Claus Gyrup
IPC分类号： C07K14/435 , C07K14/47 , C07K16/18 , C12N9/64 , C07K16/40 , A61K38/17
CPC分类号： C07K14/4715 , A61K38/00 , C07K16/40 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C12N9/6489

89. 发明授权

EP2767587B1 Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders 有权
标题翻译：因子IX的凝血活性的变体在缺乏其辅因子及其对出血性疾病的治疗
公开(公告)号：EP2767587B1
公开(公告)日：2017-04-05
申请号：EP14165396.4
申请日：2009-07-28
申请人： DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH
发明人： Seifried, Erhard , Schüttrumpf, Jörg
IPC分类号： C12N9/64
CPC分类号： C12N9/644 , C12Y304/21022

90. 发明公开

EP3029071A4 SAXATILIN-FC FUSION PROTEIN AND USE THEREOF 有权
标题翻译： SAXATALIN-Fc融合蛋白和使用THEREOF-
公开(公告)号：EP3029071A4
公开(公告)日：2017-03-22
申请号：EP14831205
申请日：2014-07-30
申请人： INDUSTRY-ACADEMIC COOP FOUND YONSEI UNIV
发明人： HONG SUNG YU , HEO JI HOE , KWON IL , KIM DONG IK , JANG YANG SOO , KIM YOUNG DAE
IPC分类号： C07K19/00 , A61K38/00 , A61K38/17 , A61P9/00 , C07K14/46 , C12N9/64 , C12N15/62
CPC分类号： C07K14/46 , A61K38/00 , C07K2319/30 , C12N9/6489
摘要： The present invention relates to a saxatilin derivative having an increased half life and a use thereof. The saxatilin derivative of the present invention has thrombolytic ability similar to that of saxatilin, which is the mother protein, a remarkably increased protein half life, and efficiently dissolves, for long period of time, blood clots already formed in blood vessels of an animal model with a FeCl 3 -induced carotid by using the same. Therefore, a composition containing, as an active ingredient, the saxatilin derivative of the present invention does not cause reocclusion after penetration and effectively opens to microvessels, and is thus very useful for treating angiostenosis or occlusive diseases (for example, cerebrovascular diseases, cardiovascular diseases, arteriosclerotic vascular diseases, coronary artery diseases, and peripheral vascular diseases).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式